Congenica Appoints New CEO
Congenica, a global provider of clinical genomics interpretation software, today announced the appointment of its new Chief Executive Officer David Atkins, Ph.D. Based at the Companys headquarters in Cambridge, UK, Dr Atkins also joins Congenicas Board of Directors.
Dr Atkins has over 25 years experience as a global leader in a broad range of diagnostics and healthcare businesses. He has held senior positions in R&D, business development, operations and sales and marketing. He has extensive commercial experience in markets in North America, EMEA, Asia and Latin America.
Prior to joining Congenica, Dr Atkins was previously CEO of Synevo, a clinical diagnostic laboratory service business operating across Germany and Eastern Europe. Past roles also include global head of the Advanced Staining pathology business unit for Leica Biosystems, a Danaher Company. Dr Atkins also has over 20 years experience with Johnson & Johnsons Medical Device and Diagnostic businesses in R&D and business development and most recently senior international commercial roles.
Welcoming Dr Atkins to the Company, Dr Andy Richards, Chairman of Congenica, said: David has an impressive international track record of success in leading and scaling healthcare technology companies. I am delighted that he has chosen to join Congenica at this pivotal time in the Companys development.
Dr Atkins succeeds co-founder and CEO Dr. Tom Weaver, who will continue to serve on the Board, as well as interim-CEO Dr. Nick Lench, who will continue in his COO role. Dr Weaver said: I am really excited that David will lead the next phase of our business. There is no better time for someone with his talent and experience to join our executive team and drive our rapid growth.